Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant
- Benitec to receive upfront cash payment of US$10 million with additional cash payments totalling US$17.5 million (a total of US$27.5M) upon completion of near-term milestones for BB-301, now named A...
Page (1) of 1 - 07/08/18||
(July 08, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved